Business
TechCare Receives CE Mark Approval for Novokid Lice Treatment Device
TechCare Receives CE Mark Approval for Novokid Lice Treatment Device.
About this update from Citrine Global Corp.
[{"type":"text","content":"\n\n\n\nTechCare Receives CE Mark Approval for Novokid Lice Treatment Device\n\n\n\n\n\nTechCare Receives CE Mark Approval for Novokid Lice Treatment Device\nApproval Clears the Way for Distribution of TechCare's Novokid Products in 28 Countries Across Europe commencing in Q4, Complementing the Company's Recently Announced Strategic Partnership with HoMedics\nPR Newswire\nROSH HA'AIN, Israel, August 22, 2017\n\n\n\nROSH HA'AIN, Israel, August 22, 2017 /PRNewswire/ --\n\nTechCare Corp. (OTCQB: TECR), a technology company with a revolutionary delivery platform that uses vapor technology for natural health and beauty treatments, today announced its Novokid has received CE Mark approval as a CLASS I Medical Device.\n\nThe approval is in line with the Company's projected milestones to obtain CE approval during Q3 and to commence sales in Europe during Q4. This achievement complements the recently announced strategic partnership with HoMedics for the North and South American markets.\n\nNovokid is the first of its kind home use device, presenting a scientifically proven solution to eliminate lice, super lice and eggs. Novokid is 100% natural, plant-based and pesticide-free.   Utilizing a proprietary vapor-based delivery platform, Novokid employs a simple 10 minute dry treatment that requires no rinsing or washing. The treatment is fast, dry, clean and easily administered at home or on the go. Novokid can also be used as a maintenance and preventative treatment if used regularly.\n\n\"This is a major milestone for our company and an important step towards widespread availability of a scientifically proven, pesticide-free, simple and easy-to-use treatment for lice,\" stated Zvi Yemini, Chairman and CEO of TechCare Corp. \"Receiving approval to utilize the CE Mark clears the way for product distribution in 28 countries across Europe. The treatment of head lice is a $1.8 billion market globally, and the market in Europe is estimated to exceed $500 million. Combined with our milestone strategic partnership with HoMedics for the Americas, this achievement will help us initiate distribution agreements throughout Europe commencing in Q4.\"\n\nZvi Yemini, Chairman and CEO of TechCare Corp., added, \"For those infected with lice, the treatment options have been limited to pesticide-based solutions that have very limited efficacy ...